The approval for Trulicity in the new indication is for type 2 diabetes with established cardiovascular (CV) disease or multiple cardiovascular risk factors. The glucagon-like peptide 1 receptor The post Trulicity gets FDA nod for reducing CV risk in type 2 diabetes patients appeared first on Pharmaceutical Business review.
Mon Feb 24, 2020 14:28
The results demonstrated an excellent safety profile and potent IgG reduction capability. The full study will be presented at an upcoming international conference. Based on the results of The post Harbour BioMed announces completion of phase 1 study in China of HBM9161, an anti-FcRn antibody appeared first on Pharmaceutical Business review.
Mon Feb 24, 2020 13:27
Committed to advancing the research and development process and clinical utility of biopharmaceutical companies’ novel biomarker-driven oncology drug, Genetron Health has already formed partnerships with dozens of leading The post Genetron Health, InnoCare collaborate to accelerate development and commercialisation of novel drugs for cancer treatment appeared first on Pharmaceutical Business review.
Mon Feb 24, 2020 12:27
Claimed to be the first FDA-approved intravenous (IV) treatment for migraine prevention, the Vyepti will be available from April and the recommended dose is 100mg for every three The post Lundbeck gets FDA nod for migraine prevention drug Vyepti appeared first on Pharmaceutical Business review.
Mon Feb 24, 2020 10:26
Publication date: Available online 21 February 2020Source: Contemporary Clinical TrialsAuthor(s): Maya K. Vadiveloo, Xintong Guan, Haley W. Parker, Elie Perraud, Ashley Buchanan, Stephen Atlas, Anne N. ThorndikeAbstractBackground/AimsHealth stakeholders are interested in the promise of healthy food incentives to improve dietary quality. The Smart Cart Study tested whether targeting healthful food incentives based on customer preferences and purchase history was effective for improving grocery purchase...
Sat Feb 22, 2020 14:53
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου